Potential for proteasome inhibition in the treatment of cancer - PubMed (original) (raw)
Review
Potential for proteasome inhibition in the treatment of cancer
Julian Adams. Drug Discov Today. 2003.
Abstract
Proteasome inhibition is a new approach to treating cancer. Proteasome inhibitors specifically induce apoptosis in cancer cells, but most proteasome inhibitors are not suitable for clinical development. Peptide boronates overcome the shortcomings of earlier generation proteasome inhibitors, and bortezomib (VELCADE; formerly PS-341) is the first peptide boronate to enter clinical trials. Preclinical studies of bortezomib have demonstrated antitumor activity in a variety of tumor types. Phase I trials provided evidence of manageable toxicities and support a twice-weekly dosing regimen now being examined in a Phase III study.
Comment in
- Proteasome inhibitors in the treatment of cancer.
Golab J. Golab J. Drug Discov Today. 2003 Jul 1;8(13):575. doi: 10.1016/s1359-6446(03)02729-6. Drug Discov Today. 2003. PMID: 12850331 No abstract available.
Similar articles
- Cancer research. Taking garbage in, tossing cancer out?
Garber K. Garber K. Science. 2002 Jan 25;295(5555):612-3. doi: 10.1126/science.295.5555.612. Science. 2002. PMID: 11809952 No abstract available. - Development of the proteasome inhibitor Velcade (Bortezomib).
Adams J, Kauffman M. Adams J, et al. Cancer Invest. 2004;22(2):304-11. doi: 10.1081/cnv-120030218. Cancer Invest. 2004. PMID: 15199612 Review. - Proteasome inhibition: a novel approach to cancer therapy.
Adams J. Adams J. Trends Mol Med. 2002;8(4 Suppl):S49-54. doi: 10.1016/s1471-4914(02)02315-8. Trends Mol Med. 2002. PMID: 11927288 Review. - Proteasome inhibition in cancer: development of PS-341.
Adams J. Adams J. Semin Oncol. 2001 Dec;28(6):613-9. doi: 10.1016/s0093-7754(01)90034-x. Semin Oncol. 2001. PMID: 11740819 Review. - Molecule of the month. Bortezomib.
[No authors listed] [No authors listed] Drug News Perspect. 2003 Jun;16(5):324. Drug News Perspect. 2003. PMID: 12942163 No abstract available.
Cited by
- Synthesis and anti-cancer activities of a water soluble gold(III) porphyrin.
Lammer AD, Cook ME, Sessler JL. Lammer AD, et al. J Porphyr Phthalocyanines. 2015 Jan;19(1-03):398-403. doi: 10.1142/S1088424615500236. J Porphyr Phthalocyanines. 2015. PMID: 25914517 Free PMC article. - Bortezomib Is Toxic but Induces Neurogenesis and Inhibits TUBB3 Degradation in Rat Neural Stem Cells.
Sohn SY, San TT, Kim J, Kim HJ. Sohn SY, et al. Biomol Ther (Seoul). 2024 Jan 1;32(1):65-76. doi: 10.4062/biomolther.2023.134. Epub 2023 Dec 11. Biomol Ther (Seoul). 2024. PMID: 38072501 Free PMC article. - 1,10-Phenanthroline promotes copper complexes into tumor cells and induces apoptosis by inhibiting the proteasome activity.
Zhang Z, Bi C, Schmitt SM, Fan Y, Dong L, Zuo J, Dou QP. Zhang Z, et al. J Biol Inorg Chem. 2012 Dec;17(8):1257-67. doi: 10.1007/s00775-012-0940-x. Epub 2012 Oct 9. J Biol Inorg Chem. 2012. PMID: 23053530 Free PMC article. - Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Chen D, Landis-Piwowar KR, Chen MS, Dou QP. Chen D, et al. Breast Cancer Res. 2007;9(6):R80. doi: 10.1186/bcr1797. Breast Cancer Res. 2007. PMID: 18300387 Free PMC article. - Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model.
Mlynarczuk-Bialy I, Doeppner TR, Golab J, Nowis D, Wilczynski GM, Parobczak K, Wigand ME, Hajdamowicz M, Biały LP, Aniolek O, Henklein P, Bähr M, Schmidt B, Kuckelkorn U, Kloetzel PM. Mlynarczuk-Bialy I, et al. Transl Oncol. 2014 Oct 24;7(5):570-9. doi: 10.1016/j.tranon.2014.07.002. eCollection 2014 Oct. Transl Oncol. 2014. PMID: 25389452 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources